These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12860490)

  • 1. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Berlin, Germany, November 19, 2001.
    Pollard S; Nashan B; Johnston A; Hoyer P; Belitsky P; Keown P; Helderman H;
    Clin Ther; 2003 Jun; 25(6):1654-69. PubMed ID: 12860490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generic cyclosporine formulations: more open questions than answers.
    Cattaneo D; Perico N; Remuzzi G
    Transpl Int; 2005 Apr; 18(4):371-8. PubMed ID: 15773953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients.
    Johnston A; Belitsky P; Frei U; Horvath J; Hoyer P; Helderman JH; Oellerich M; Pollard S; Riad H; Rigotti P; Keown P; Nashan B
    Eur J Clin Pharmacol; 2004 Aug; 60(6):389-95. PubMed ID: 15205865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients.
    Cortinovis M; Gotti E; Trillini M; Carrara F; Gaspari F; Ruggenenti P; Remuzzi G; Perico N
    Nephron; 2017; 135(3):173-180. PubMed ID: 27941326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic cyclosporine: a word of caution.
    Ponticelli C
    J Nephrol; 2004; 17 Suppl 8():S20-4. PubMed ID: 15599881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).
    Noble S; Markham A
    Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare costs in renal transplant recipients using branded versus generic ciclosporin.
    Helderman JH; Kang N; Legorreta AP; Chen JY
    Appl Health Econ Health Policy; 2010; 8(1):61-8. PubMed ID: 20038194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
    Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL
    Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporin C2hour monitoring after renal transplantation.
    Einecke G; Mai I; Fritsche L; Slowinski T; Waiser J; Glander P; Böhler T; Neumayer HH; Budde K
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):477-81. PubMed ID: 14703954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from Sandimmune to Neoral in organ transplant recipients.
    Bartucci MR; Bayer L; Brooks BK; Chandler L; Himes V; Meiergerd D; Newby B; Satmary NT; Shieck V
    J Transpl Coord; 1998 Dec; 8(4):227-33; quiz 234-5. PubMed ID: 10205463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of generic cyclosporine arpimune in Filipino low-risk primary kidney transplant recipients.
    Pamugas GE; Danguilan RA; Lamban AB; Mangati VB; Ona ET
    Transplant Proc; 2012 Jan; 44(1):101-8. PubMed ID: 22310590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss?
    He X; Johnston A
    Transplant Proc; 2004 Jun; 36(5):1321-6. PubMed ID: 15251323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
    Canadian Neoral Renal Transplantation Study Group
    Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients.
    Hibberd AD; Trevillian PR; Roger SD; Wlodarczyk JH; Stein AM; Bohringer EG; Milson-Hawke SM
    Transplantation; 2006 Mar; 81(5):711-7. PubMed ID: 16534473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin.
    Riva N; Guido PC; Ibañez J; Licciardone N; Rousseau M; Mato G; Monteverde M; Schaiquevich P
    Int J Clin Pharm; 2014 Aug; 36(4):779-86. PubMed ID: 24861769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation.
    Roza A; Tomlanovich S; Merion R; Pollak R; Wright F; Rajagopalan P; Pruett T; Scandling J; Ryan J; Awni W; Schweitzer S; Greco R; Lam W; Nabulsi A; Hoffman R
    Transplantation; 2002 Oct; 74(7):1013-7. PubMed ID: 12394847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability, Efficacy and Safety of Generic Immunosuppressive Drugs for Kidney Transplantation: A Systematic Review and Meta-Analysis.
    Tsipotis E; Gupta NR; Raman G; Zintzaras E; Jaber BL
    Am J Nephrol; 2016; 44(3):206-18. PubMed ID: 27576318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function.
    Qazi YA; Forrest A; Tornatore K; Venuto RC
    Clin Transplant; 2006; 20(3):313-7. PubMed ID: 16824147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients.
    Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J
    Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.